首页> 美国卫生研究院文献>PLoS Clinical Trials >Crosstalks of the PTPIP51 interactome revealed in Her2 amplified breast cancer cells by the novel small molecule LDC3/Dynarrestin
【2h】

Crosstalks of the PTPIP51 interactome revealed in Her2 amplified breast cancer cells by the novel small molecule LDC3/Dynarrestin

机译:新型小分子LDC3 / Dynarrestin在Her2扩增的乳腺癌细胞中揭示了PTPIP51相互作用组的串扰。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

LDC3/Dynarrestin, an aminothiazole derivative, is a recently developed small molecule, which binds protein tyrosine phosphatase interacting protein 51 (PTPIP51). PTPIP51 interacts with various proteins regulating different signaling pathways leading to proliferation and migration. Her2 positive breast cancer cells (SKBR3) express high levels of PTPIP51. Therefore, we investigated the effects of LDC3/Dynarrestin on PTPIP51 and its interactome with 12 different proteins of various signal pathways including the interaction with dynein in SKBR3 cells. The localization and semi-quantification of PTPIP51 protein and the Tyr176 phosphorylated PTPIP51 protein were evaluated. Protein-protein-interactions were assessed by Duolink proximity ligation assays. Interactions and the activation of signal transduction hubs were examined with immunoblots. LDC3/Dynarrestin led to an increased PTPIP51 tyrosine 176 phosphorylation status while the overall amount of PTPIP51 remained unaffected. These findings are paralleled by an enhanced interaction of PTPIP51 with its crucial kinase c-Src and a reduced interaction with the counteracting phosphatase PTP1B. Furthermore, the treatment results in a significantly augmented interaction of PTPIP51/14-3-3β and PTPIP51/Raf1, the link to the MAPK pathway. Under the influence of LDC3/Dynarrestin, the activity of the MAPK pathway rose in a concentration-dependent manner as indicated by RTK assays and immunoblots. The novel small molecule stabilizes the RelA/IκB/PTPIP51 interactome and can abolish the effects caused by TNFα stimulation. Moreover, LDC3/Dynarrestin completely blocked the Akt signaling, which is essential for tumor growth. The data were compared to the recently described interactome of PTPIP51 in LDC3/Dynarrestin treated non-cancerous keratinocyte cells (HaCaT). Differences were identified exclusively for the mitochondrial-associated ER-membranes (MAM) interactions and phospho-regulation related interactome of PTPIP51.LDC3/Dynarrestin gives the opportunity/possibility to influence the MAPK signaling, NFkB signaling and probably calcium homeostasis in breast cancer cells by affecting the PTPIP51 interactome.
机译:LDC3 / Dynarrestin是一种氨基噻唑衍生物,是最近开发的小分子,与蛋白酪氨酸磷酸酶相互作用蛋白51(PTPIP51)结合。 PTPIP51与调节不同信号通路的各种蛋白质相互作用,导致增殖和迁移。 Her2阳性乳腺癌细胞(SKBR3)表达高水平的PTPIP51。因此,我们研究了LDC3 / Dynarrestin对PTPIP51及其与12种不同信号通路蛋白的相互作用蛋白的相互作用,这些蛋白包括在SKBR3细胞中与动力蛋白的相互作用。评价了PTPIP51蛋白和Tyr176磷酸化的PTPIP51蛋白的定位和半定量。蛋白-蛋白相互作用通过Duolink邻近结扎法进行评估。用免疫印迹检查相互作用和信号转导中心的激活。 LDC3 / Dynarrestin导致PTPIP51酪氨酸176磷酸化状态增加,而PTPIP51的总量保持不变。这些发现与PTPIP51及其关键激酶c-Src的增强相互作用以及与抗磷酸酶PTP1B的相互作用降低相对应。此外,该治疗导致PTPIP51 /14-3-3β和PTPIP51 / Raf1(与MAPK途径的联系)之间的相互作用大大增强。如RTK测定和免疫印迹所示,在LDC3 / Dynarrestin的影响下,MAPK途径的活性以浓度依赖性方式上升。这种新颖的小分子可以稳定RelA /IκB/ PTPIP51相互作用组,并且可以消除TNFα刺激引起的影响。此外,LDC3 / Dynarrestin完全阻断了Akt信号传导,这对于肿瘤的生长至关重要。将数据与最近描述的LDC3 / Dynarrestin处理的非癌性角质形成细胞(HaCaT)中PTPIP51的相互作用组进行比较。差异仅针对线粒体相关的ER膜(MAM)相互作用和PTPIP51的磷酸调节相关的相互作用组进行了鉴定。影响PTPIP51相互作用组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号